ArticleCancer immunology, immunotherapy : CII2026

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium.

Takafumi Yanagisawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.